Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eupraxia PharmaceuticalsTSX:EPRX +2.31%36 5-Year Share Buyback Ratio is -32.90 as of Jun. 2026. GuruFocus rates TSX:EPRX with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 1,121 Biotechnology companies, Eupraxia Pharmaceuticals ranks worse than 80.37% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Eupraxia Pharmaceuticals's current 5-Year Share Buyback Ratio was -32.90%.
TSX:EPRX's 5-Year Share Buyback Ratio is ranked worse than 80.37% of 1121
companies
in the Biotechnology industry
Industry Median: -10.2
vs TSX:EPRX: -32.90
Eupraxia Pharmaceuticals (TSX:EPRX) 5-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Eupraxia Pharmaceuticals 5-Year Share Buyback Ratio Related Terms
TSX:EPRX vs VRTX, REGN, MRNA: 5-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Eupraxia Pharmaceuticals's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eupraxia Pharmaceuticals 5-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eupraxia Pharmaceuticals's 5-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Eupraxia Pharmaceuticals's 5-Year Share Buyback Ratio falls into.
Eupraxia Pharmaceuticals 5-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 5-Year Share Buyback Ratio of -32.90 mean?
Eupraxia Pharmaceuticals (TSX:EPRX) has a 5-Year Share Buyback Ratio of -32.90 as of Jun. 2026. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Eupraxia Pharmaceuticals and its competitors. According to the industry distribution chart, Eupraxia Pharmaceuticals ranks #901 out of 1121 companies in the Biotechnology industry, placing it in the top 80.4%.
Is Eupraxia Pharmaceuticals' 5-Year Share Buyback Ratio too high?
Eupraxia Pharmaceuticals' current 5-Year Share Buyback Ratio is -32.90. Based on the distribution chart, Eupraxia Pharmaceuticals ranks #901 out of 1121 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Eupraxia Pharmaceuticals has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Eupraxia Pharmaceuticals' 5-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Eupraxia Pharmaceuticals ranks #901 out of 1121 companies for 5-Year Share Buyback Ratio. This places Eupraxia Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Share Buyback Ratio for a Biotechnology company?
A good 5-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 5-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Share Buyback Ratio mean?
A high 5-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Eupraxia Pharmaceuticals and its competitors. Eupraxia Pharmaceuticals's current 5-Year Share Buyback Ratio is -32.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eupraxia Pharmaceuticals stock overvalued right now?
Eupraxia Pharmaceuticals (TSX:EPRX) has a current 5-Year Share Buyback Ratio of -32.90. The current 5-Year Share Buyback Ratio is -32.90. Eupraxia Pharmaceuticals' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Share Buyback Ratio calculated?
5-Year Share Buyback Ratio is calculated from a company's financial statements. For Eupraxia Pharmaceuticals (TSX:EPRX), the current 5-Year Share Buyback Ratio is -32.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company based in Canada that develops locally delivered, extended-release formulations of existing drugs. Its lead product candidate, EP-104, uses the company's proprietary Diffusphere technology to provide sustained drug release at the site of disease. EP-104 is being developed in two main programs: EP-104IAR for chronic knee osteoarthritis pain, which has completed a Phase 2b trial, and EP-104GI for eosinophilic esophagitis. The company targets specialty and hospital-based markets where localized, long-acting delivery may offer advantages over systemic administration. As a clinical-stage company, Eupraxia does not yet generate product revenue; it funds operations through equity financings, partnerships, and government or research grants, and its future revenue depends on regulatory approval and commercialization of its pipeline candidates.
36GF Score
Get the complete analysis for TSX:EPRX
5-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:EPRX has been successfully added to your 
